Litigation Details for Hartenstine v. Shire U.S., Inc. (D. Mass. 2015)
✉ Email this page to a colleague
Hartenstine v. Shire U.S., Inc. (D. Mass. 2015)
| Docket | ⤷ Try a Trial | Date Filed | 2015-12-18 |
| Court | District Court, D. Massachusetts | Date Terminated | 2017-02-20 |
| Cause | 28:1332 Diversity-(Citizenship) | Assigned To | Allison Dale Burroughs |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 6,322,819; 6,605,300 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Hartenstine v. Shire U.S., Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for Hartenstine v. Shire U.S., Inc. (D. Mass. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2015-12-18 | 1 | Complaint | Shire’s Adderall XR patent portfolio consists of U.S. Patent Nos. 6,322,819 (‘819 Patent) and 6,605,300 (…applied a patent procurement strategy known as “evergreening.” “Evergreened” patents are patents not on … the ‘819 and ‘300 Patents, as well as Shire’s 6,916,768 Patent (the ‘768 Patent, discussed infra), … average patent application gets approximately 15-20 hours of review time by the U.S. Patent and Trademark…thousands of patent applications each year, approximately eighty-five percent (85%) of patent applications | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
